• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

    11/22/22 8:00:00 AM ET
    $VIVO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VIVO alert in real time by email

    CINCINNATI, Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022.

    Meridian Bioscience, Inc. Logo (PRNewsfoto/Meridian Bioscience, Inc.)

    Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021):

    • Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-year
    • Diagnostics segment net revenues increased 14% year-over-year to $39.2 million
    • Life Science segment delivered net revenues of $26.5 million, a decrease of 37%
    • Submitted 510(k) for Curian® Shiga Toxin assay

    Full Fiscal Year 2022 Highlights (Comparison to Full Year Fiscal 2021):

    • Consolidated net revenues of $333.0 million, up 5% year-over-year
    • Diagnostics segment net revenues increased 22% year-over-year to $155.9 million
    • Life Science segment delivered net revenues of $177.1 million, a decrease of 7%
    • Established new Life Science recombinant protein R&D facility in New Jersey with assets acquired from EUPROTEIN, Inc.
    • Diagnostics segment launched two new products: Curian® Campy and Revogene® SARS-CoV-2 EUA
    • Life Science segment launched 17 new molecular products, which completed a full line of sample-specific master mixes for qPCR and LAMP with sensitivity suitable for oncology applications
    • Entered into agreement to be acquired by a Korean Consortium for $34.00 per share, which is expected to close before the end of calendar year 2022

    Fourth Quarter Fiscal 2022 Results (Comparison to Fourth Quarter Fiscal 2021)

    Consolidated net revenues for the fourth quarter of fiscal 2022 decreased 14% to $65.7 million, compared to $76.2 million last year.  Diagnostics segment net revenues increased 14% year-over-year, while Life Science segment net revenues decreased 37%.  Growth in the Diagnostics segment was driven by our non-molecular assay products which increased 22%.  Key contributors to the non-molecular assay year-over-year increase include organic growth in our BreathID® product line, the addition of the BreathTek® product line acquired in July 2021 and the increase in sales of LeadCare® products that were not shipping for a portion of the fourth quarter of fiscal 2021 due to a product recall.  The Life Science segment decline was driven by lower overall demand, primarily from reductions in COVID-19 testing, though more so for molecular reagents (53% decrease) than immunological reagents (8% decrease).

    Reported consolidated operating income for the fourth quarter of fiscal 2022 was $4.6 million (7% margin), compared to $8.5 million (11% margin) in the fourth quarter of fiscal 2021.  The decrease in consolidated operating income primarily results from the decreased level of net revenues and gross margins within the Life Science segment, which resulted from the overall decline in COVID-19 related net revenues and the significant shift in product mix from the high margin molecular reagents to lower margin immunological reagents (approximately 46% molecular in fiscal 2022 versus approximately 63% in 2021).  The effect of these factors was partially offset by the decrease in overall operating expense, most notably due to the $5.6 million of product recall costs in fiscal 2021.  On an adjusted basis, consolidated operating income was $9.1 million, reflecting a margin of 14%, down from the prior year quarter's $13.3 million and 17% margin (see non-GAAP financial measure reconciliation below), reflecting the factors noted above.

    Full Fiscal Year 2022 Results (Comparison to Full Year Fiscal 2021)

    Consolidated net revenues for the fiscal year ended September 30, 2022 increased 5% to $333.0 million, compared to $317.9 million in fiscal 2021.  Diagnostics segment net revenues were up 22%, while Life Science segment net revenues were down 7%.  Our Diagnostics segment experienced a 5% decrease in net revenues from our molecular products, and net revenues from our non-molecular assay products increased 27%, significantly impacted by the current year contributions of the BreathTek product line acquired in July 2021, as well as organic growth of our BreathID products.  The Life Science segment experienced a significant shift in net revenues product mix from molecular reagents (30% decrease) to immunological products (43% increase).  This shift resulted from lower overall demand for our molecular reagents in fiscal 2022, particularly the second half of the year, relative to the strong demand experienced in fiscal 2021 driven largely by reductions in COVID-19 testing, as well as the shift from molecular testing to rapid antigen testing.

    Reported consolidated operating income for the fiscal year ended September 30, 2022 was $54.4 million (16% margin), compared to $93.0 million (29% margin) in fiscal 2021.  The decrease in consolidated operating income reflects the impact of decreased level of net revenues and gross margins within the Life Science segment, which resulted from the overall decline in COVID-19 related net revenues and the significant shift in product mix mentioned above (approximately 52% molecular in fiscal 2022 versus approximately 69% in 2021), and increased operating expenses.  The increase in operating expenses primarily results from:  (i) a $10.0 million estimated expense related to the possible resolution of the previously disclosed and ongoing U.S. Department of Justice legal matter; (ii) higher acquisition and transaction related expenses in connection with the definitive merger agreement signed in July 2022; (iii) increased selling and marketing costs in both the Diagnostics and Life Science segments, due, in part, to filling certain open positions and easing of COVID-19 related travel and meeting restrictions; and (iv) increased general and administrative costs due, in part, to increased incentive compensation expenses and increased intangible amortization resulting from the July 2021 BreathTek acquisition.  The effect of these factors was partially offset by a decrease in product recall expenses during fiscal 2022, following the recording of a $5.6 million LeadCare product recall reserve recorded in fiscal 2021.  On an adjusted basis, consolidated operating income was $76.0 million, reflecting a margin of 23%, down from the prior year quarter's $95.3 million and 30% margin (see non-GAAP financial measure reconciliation below), reflecting the factors noted above.

    Jack Kenny, Chief Executive Officer, commented, "Meridian delivered strong financial performance for the third straight year, yet again exceeding our expectations going into the year.  Our Diagnostics and Life Science segments both performed well, generating positive Operating Income, and I am excited for the future prospects of both businesses."

    Financial Condition

    In fiscal year 2022, the Company generated Cash from Operations of $82.4 million, a 23% increase from $66.9 million in fiscal 2021.  This contributed to a cash and cash equivalents balance of $81.5 million at September 30, 2022.  The Company's obligations under its commercial bank credit facility totaled $25.0 million as of September 30, 2022, leaving $175.0 million of available borrowing capacity under the facility. 

    Andy Kitzmiller, Chief Financial Officer, commented, "Meridian continued its track record of significant cash generation, even on lower operating profit, through its focus on the efficiency of the cash conversion cycle throughout the year.  Our strong balance sheet and operating fundamentals position the Company well as we navigate the current macroeconomic uncertainty and establish a new baseline for the Life Science segment in the endemic phase of the COVID-19 pandemic."

    Subsequent Event

    On October 26, 2022, Meridian acquired select assets from Estel Biosciences, Inc., as part of Meridian's continued investment in its immunological research and development capabilities.  Among other assets, the Company acquired intellectual property that will be incorporated into the Life Science operations in North Brunswick, New Jersey and Memphis, Tennessee for the design and manufacture of recombinant proteins using an insect cell expression system.

    Update on the Pending Transaction, Fiscal 2023 Guidance, and Conference Call

    As announced on July 7, 2022, the Company entered into a definitive merger agreement (the "Merger Agreement") whereby a newly formed affiliate vehicle of a Consortium, consisting of SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), will acquire Meridian (the "Merger").  The closing of the transaction is subject to receipt of required regulatory approvals, the absence of specified material adverse outcomes of the Company's previously disclosed and ongoing investigation by the U.S. Department of Justice, and other customary closing conditions.  

    On October 10, 2022, Meridian held a special meeting of its shareholders, at which the Company's shareholders approved the transaction.  As of November 22, 2022, Meridian or the appropriate parties to the Merger Agreement have obtained approval or clearances, as applicable, for all relevant antitrust and foreign direct investment filings, including the filing related to the Committee on Foreign Investment in the United States ("CFIUS") which was obtained on November 21, 2022.  Meridian has not yet reached a resolution with the DOJ with respect to the DOJ legal matter; Meridian continues to actively work with the DOJ to find a resolution to the DOJ legal matter.

    As of November 22, 2022, Meridian continues to expect to complete the Merger before the end of calendar year 2022.

    Due to the pending transaction, Meridian is no longer holding conference calls to discuss its quarterly financial results and has issued no financial guidance for fiscal year 2023.

     

    FOURTH QUARTER AND FISCAL 2022 OPERATING RESULTS

    (In Thousands, Except per Share Data)



    The following table sets forth the comparative results of Meridian on a U.S. GAAP basis for the interim and

    annual periods of fiscal 2022 and fiscal 2021.









    (Unaudited)











    Three Months Ended



    Twelve Months Ended







    September 30,



    September 30,







    2022



    2021



    2022



    2021

    Net revenues

    $

    65,675



    $

    76,204



    $

    333,018



    $

    317,896

    Cost of sales



    31,683





    31,487





    144,662





    116,748





    Gross profit



    33,992





    44,717





    188,356





    201,148





























    Operating expenses

























    Research and development



    6,407





    6,112





    24,335





    23,911



    Selling and marketing



    7,840





    7,010





    31,273





    26,780



    General and administrative



    10,982





    12,714





    57,148





    49,541



    Product recall costs (adjustment)



    (350)





    5,596





    (350)





    5,596



    Acquisition and transaction related costs



    2,645





    92





    6,940





    392



    Litigation and select legal costs



    909





    108





    13,510





    2,803



    Restructuring costs



    911





    -





    1,109





    -



    Change in fair value of acquisition

























       consideration and settlement



    -





    4,596





    -





    (909)





    Total operating expenses



    29,344





    36,228





    133,965





    108,114





























    Operating income



    4,648





    8,489





    54,391





    93,034

    Other income (expense), net



    (15)





    (633)





    (74)





    (2,583)



    Earnings before income taxes



    4,633





    7,856





    54,317





    90,451



    Income tax provision (benefit)



    (1,072)





    1,199





    11,858





    19,044



    Net earnings

    $

    5,705



    $

    6,657



    $

    42,459



    $

    71,407





























    Net earnings per basic common share

    $

    0.13



    $

    0.15



    $

    0.97



    $

    1.65

    Basic common shares outstanding



    43,749





    43,356





    43,583





    43,259





























    Net earnings per diluted common share

    $

    0.13



    $

    0.15



    $

    0.96



    $

    1.62

    Diluted common shares outstanding



    44,732





    44,094





    44,375





    44,012

     

    Adjusted Financial Measures (in thousands, except per share data)

    (see non-GAAP financial measure reconciliation below)











    Three Months Ended



    Twelve Months Ended









    September 30,



    September 30,





    2022



    2021



    2022



    2021



    Adjusted operating income

    $

    9,113



    $

    13,285



    $

    75,950



    $

    95,320





    Adjusted net earnings



    9,090





    10,258





    61,172





    73,123





    Adjusted net earnings per diluted

         common share

    $

    0.20



    $

    0.23



    $

    1.38



    $

    1.66



























































     

    Condensed Consolidated Balance Sheet Data (in thousands)







    September 30,



    2022





    2021

    Cash and equivalents

    $

    81,453



    $

    49,771

    Working capital  



    152,646





    145,650

    Long-term debt



    25,000





    60,000

    Shareholders' equity



    368,061





    328,302

    Total assets



    463,097





    449,722

     

    Segment Data

    The following table sets forth the revenue and segment data for the interim and annual periods in fiscal 2022

    and fiscal 2021 (in thousands).







    (Unaudited)











    Three Months Ended



    Twelve Months Ended







    September 30,



    September 30,







    2022



    2021



    2022



    2021



     

    Net Revenues - By Product Platform/Type

























    Diagnostics



























    Molecular assays

    $

    4,138



    $

    5,671



    $

    18,177



    $

    19,037





    Non-molecular assays



    35,049





    28,630





    137,726





    108,723





         Total Diagnostics



    39,187





    34,301





    155,903





    127,760



    Life Science



























    Molecular reagents



    12,285





    26,399





    91,816





    130,537





    Immunological reagents



    14,203





    15,504





    85,299





    59,599





         Total Life Science



    26,488





    41,903





    177,115





    190,136





              Total Net Revenues

    $

    65,675



    $

    76,204



    $

    333,018



    $

    317,896









































































     





    (Unaudited)









    Three Months Ended



    Twelve Months Ended





    September 30,



    September 30,





    2022



    2021



    2022



    2021

     

    Net Revenues - By Disease State/Geography























    Diagnostics

























    Gastrointestinal assays

    $

    22,864



    $

    19,838



    $

    87,568



    $

    68,890



    Respiratory illness assays



    5,273





    5,375





    26,632





    17,608



    Blood chemistry assays



    4,430





    2,391





    14,189





    15,398



    Other



    6,620





    6,697





    27,514





    25,864



         Total Diagnostics



    39,187





    34,301





    155,903





    127,760

    Life Science

























    Americas



    7,465





    6,356





    33,062





    46,063



    EMEA



    10,982





    23,965





    81,305





    93,655



    ROW



    8,041





    11,582





    62,748





    50,418



         Total Life Science



    26,488





    41,903





    177,115





    190,136



              Total Net Revenues

    $

    65,675



    $

    76,204



    $

    333,018



    $

    317,896



























    OPERATING INCOME (LOSS)

























    Diagnostics

    $

    (122)



    $

    (11,680)



    $

    2,982



    $

    (7,280)



    Life Science



    10,064





    23,182





    86,040





    115,014



    Corporate



    (5,300)





    (3,034)





    (34,707)





    (14,788)



    Eliminations



    6





    21





    76





    88



       Total Operating Income

    $

    4,648



    $

    8,489



    $

    54,391



    $

    93,034





























    Geographic Regions

    Americas = North and Latin America

    EMEA = Europe, Middle East and Africa

    ROW = Rest of World













































     

    NON-GAAP FINANCIAL MEASURES

    In this press release, we have supplemented our reported GAAP financial information with information on operating expenses, operating income, operating margin, net earnings, basic net earnings per share and diluted net earnings per share, each on an adjusted basis excluding the effects of acquisition and transaction related costs, litigation and select legal costs, and changes in fair value of acquisition consideration, each of which is a non-GAAP measure.  We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic net earnings per share and diluted net earnings per share amounts reported under GAAP for the three- and twelve-month periods ended September 30, 2022 and 2021. 

    We believe this information is useful to an investor in evaluating our performance because:

    1. These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and



    2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, the non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with GAAP.  Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.

     

    FOURTH QUARTER AND FISCAL YEAR

    GAAP TO NON-GAAP RECONCILIATION TABLES

    (In Thousands, Except per Share Data)









    Three Months



    Twelve Months







    Ended September 30,



    Ended September 30,







    2022



    2021



    2022



    2021

    Operating Expenses -

























    GAAP basis

    $

    29,344



    $

    36,228



    $

    133,965



    $

    108,114



    Acquisition and transaction related costs



    (2,645)





    (92)





    (6,940)





    (392)



    Litigation and select legal costs



    (909)





    (108)





    (13,510)





    (2,803)



    Restructuring costs



    (911)





    -





    (1,109)





    -



    Change in fair value of acquisition

        consideration and settlement



    -





    (4,596)





    -





    909



        Adjusted Operating Expenses

    $

    24,879



    $

    31,432



    $

    112,406



    $

    105,828





























    Operating Income -

























    GAAP basis

    $

    4,648



    $

    8,489



    $

    54,391



    $

    93,034



    Acquisition and transaction related costs



    2,645





    92





    6,940





    392



    Litigation and select legal costs



    909





    108





    13,510





    2,803



    Restructuring costs



    911





    -





    1,109





    -



    Change in fair value of acquisition

        consideration and settlement



    -





    4,596





    -





    (909)



        Adjusted Operating Income

    $

    9,113



    $

    13,285



    $

    75,950



    $

    95,320





























    Net Earnings -

























    GAAP basis

    $

    5,705



    $

    6,657



    $

    42,459



    $

    71,407



    Acquisition and transaction related costs *



    1,986





    69





    5,212





    294



    Litigation and select legal costs *



    683





    81





    12,636





    2,105



    Restructuring costs *



    716





    -





    865





    -



    Change in fair value of acquisition

        consideration and settlement *



    -





    3,451





    -





    (683)



        Adjusted Net Earnings

    $

    9,090



    $

    10,258



    $

    61,172



    $

    73,123





























    Basic Earnings per Common Share -

























    GAAP basis

    $

    0.13



    $

    0.15



    $

    0.97



    $

    1.65



    Acquisition and transaction related costs



    0.05





    -





    0.12





    0.01



    Litigation and select legal costs



    0.02





    -





    0.29





    0.05



    Restructuring costs



    0.02





    -





    0.02





    -



    Change in fair value of acquisition

        consideration and settlement



    -





    0.08





    -





    (0.02)



        Adjusted Basic EPS **

    $

    0.21



    $

    0.24



    $

    1.40



    $

    1.69





























     







    Three Months



    Twelve Months







    Ended September 30,



    Ended September 30,







    2022



    2021



    2022



    2021

    Diluted Earnings per Common Share -

























    GAAP basis

    $

    0.13



    $

    0.15



    $

    0.96



    $

    1.62



    Acquisition and transaction related costs



    0.04





    -





    0.12





    0.01



    Litigation and select legal costs



    0.02





    -





    0.28





    0.05



    Restructuring costs



    0.02





    -





    0.02





    -



    Change in fair value of acquisition

        consideration and settlement



    -





    0.08





    -





    (0.02)



        Adjusted Diluted EPS ***

    $

    0.20



    $

    0.23



    $

    1.38



    $

    1.66































    *

    Net of tax, as applicable. 

    **

    Three months ended September 30, 2022 and 2021 do not sum to total due to rounding.

    ***

    Three months ended September 30, 2022 does not sum to total due to rounding.

     

    REVOGENE® SARS-COV-2 ASSAY DISCLAIMER

    The Revogene® SARS-CoV-2 product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.  This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.  The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner.

    FORWARD-LOOKING STATEMENTS 

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "continues", "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "signals", "should", "can", "guidance" and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian Bioscience, Inc. ("Meridian" or "the Company") expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted net earnings, sales, product demand, net revenues, operating margin, other guidance and the impact of COVID-19 on its business and prospects, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian's forward-looking statements are, and will be, based on management's then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.  These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

    Meridian's operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company's ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which the Company's customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, and in complying with the ongoing investigation of the Department of Justice described in Meridian's reports filed with the SEC, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian's operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian's growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and that the acquired businesses will be successfully integrated into Meridian's operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian's ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of future goodwill impairment testing and the impact of possible goodwill impairments on Meridian's earnings and financial results. Meridian cannot predict the possible impact of any modification or repeal of any of the provisions of current U.S. health care legislation, and any similar initiatives in other countries on Meridian's results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian's information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian's results of operations and net revenues. The Company can make no assurances that a material weakness in its internal control over financial reporting will not be identified in the future, which if identified and not properly corrected, could materially and adversely affect its operations and result in material misstatements in its consolidated financial statements. Meridian also is subject to risks and uncertainties related to the proposed acquisition by SD Biosensor, Inc., as well as disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as COVID-19, including, without limitation, related supply chain interruptions.  In addition to the factors described in this paragraph, as well as those factors identified from time to time in the Company's filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of the Company's most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on the Company's forward-looking statements.

    About Meridian Bioscience, Inc.

    Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

    Meridian's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

    Contact: 

    Charlie Wood

    Vice President – Investor Relations

    Meridian Bioscience, Inc.

    Phone:  +1 513.271.3700

    Email:  [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-reports-fourth-quarter-and-full-year-fiscal-2022-operating-results-301684525.html

    SOURCE Meridian Bioscience, Inc.

    Get the next $VIVO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VIVO

    DatePrice TargetRatingAnalyst
    2/7/2022$28.00 → $30.00Buy
    HC Wainwright & Co.
    11/15/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021

      For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

      12/10/21 1:56:40 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously

      2/7/22 6:13:53 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/15/21 6:32:31 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously

      8/9/21 6:33:26 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:22:23 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:21:33 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:20:26 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

      CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont

      1/31/23 1:56:00 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoubleVerify Holdings to Join S&P SmallCap 600

      NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf

      1/25/23 5:58:00 PM ET
      $DV
      $SPGI
      $VIVO
      Computer Software: Programming Data Processing
      Technology
      Finance: Consumer Services
      Finance
    • Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

      CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("

      12/12/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Meridian Bioscience Inc.

      15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/13/23 4:31:51 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Meridian Bioscience Inc.

      10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/9/23 8:23:24 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Meridian Bioscience Inc.

      EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/6/23 12:15:16 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Financials

    Live finance-specific insights

    See more
    • Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

      Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

      7/7/22 7:17:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

      CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

      5/6/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

      CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

      5/2/22 8:47:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

      CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.  The Company is engaging an executive search firm in the recruitment of a new chief financial officer.  The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.

      12/2/21 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Bioscience Announces Retirement of Chairman David Phillips

      CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha

      11/24/21 9:05:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/9/23 11:27:43 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/3/23 2:06:19 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      1/31/23 11:06:04 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care